Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Treatment Clinical Trials for Endometrial Cancer

Review the endometrial cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 131

Testing the addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Status: Active
Location: 370 locations
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
Status: Active
Location: 281 locations
Testing Nivolumab with or without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Status: Active
Location: 108 locations
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
Status: Active
Location: 29 locations
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Status: Active
Location: 29 locations
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Status: Active
Location: 21 locations
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Status: Active
Location: 20 locations
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
Status: Active
Location: 21 locations
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Status: Active
Location: 19 locations
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Status: Active
Location: 13 locations
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Status: Active
Location: 12 locations
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Status: Active
Location: 13 locations
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
Status: Active
Location: 11 locations
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Status: Active
Location: 12 locations
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
Status: Active
Location: 12 locations
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Status: Active
Location: 10 locations
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Status: Active
Location: 10 locations
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Status: Active
Location: 10 locations
A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies
Status: Active
Location: 8 locations
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Status: Active
Location: 8 locations
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Status: Active
Location: 8 locations
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Status: Active
Location: 9 locations
Radiation and Dostarlimab after Surgery for the Treatment of Endometrial Cancer
Status: Active
Location: 7 locations
Mirvetuximab Soravtansine for the Treatment of Folate Receptor-Alpha Positive Persistent or Recurrent Endometrial Cancer
Status: Active
Location: 7 locations
Ivonescimab for the Treatment of Metastatic or Recurrent Endometrial Cancer and Cervical Cancer
Status: Active
Location: 7 locations